Staysure continues impressive growth as it appoints new CFO
| PR Web |
Turning over £30million in 2012, up from £19million in 2011, Staysure’s success and commitment in offering quality value-for-money products and services to the 50 plus market, was further endorsed when it received ‘Best Travel Insurance Product’ in the Personal Finance Awards 2012/13 and more recently ‘Best Customer Service’ award in the 2013 UK Broker Awards.
Julie, who has recently remarried and has two children and two step children, has an impressive career history spanning both general insurance and travel, most recently in Finance Director roles at
Her appointment at Staysure follows a series of board-level hires with
Staysure has an established loyal customer base and has become one of the biggest travel insurers specialising in pre-existing medical condition cover. We see significant opportunities in both our travel insurance business and expansion in to related products and services that will best serve our customers.”
Read the full story at http://www.prweb.com/releases/2013/10/prweb11279602.htm
| Copyright: | (c) 2013 PRWEB.COM Newswire |
| Wordcount: | 372 |


Advisor News
- Global economic growth will moderate as the labor force shrinks
- Estate planning during the great wealth transfer
- Main Street families need trusted financial guidance to navigate the new Trump Accounts
- Are the holidays a good time to have a long-term care conversation?
- Gen X unsure whether they can catch up with retirement saving
More Advisor NewsAnnuity News
- Prudential launches FlexGuard 2.0 RILA
- Lincoln Financial Introduces First Capital Group ETF Strategy for Fixed Indexed Annuities
- Iowa defends Athene pension risk transfer deal in Lockheed Martin lawsuit
- Pension buy-in sales up, PRT sales down in mixed Q3, LIMRA reports
- Life insurance and annuities: Reassuring ‘tired’ clients in 2026
More Annuity NewsHealth/Employee Benefits News
Life Insurance News
- Report Summarizes Kinase Inhibitors Study Findings from Saga University Hospital (Simulation of Perioperative Ibrutinib Withdrawal Using a Population Pharmacokinetic Model and Sparse Clinical Concentration Data): Drugs and Therapies – Kinase Inhibitors
- Flawed Social Security death data puts life insurance benefits at risk
- EIOPA FLAGS FINANCIAL STABILITY RISKS RELATED TO PRIVATE CREDIT, A WEAKENING DOLLAR AND GLOBAL INTERCONNECTEDNESS
- Envela partnership expands agent toolkit with health screenings
- Legals for December, 12 2025
More Life Insurance News